Last reviewed · How we verify
NCT04895878
Patients With Co-occurrence of ANCA Vasculitis and Sjögren Syndrome
trial in ANCA Associated Vasculitis in 5 participants. Completed in 1 September 2021.
1 August 2021
Quick facts
| Lead sponsor | University Hospital, Montpellier |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 5 |
| Start date | 1 May 2021 |
| Primary completion | 1 August 2021 |
| Estimated completion | 1 September 2021 |
| Sites | 1 location across France |
Conditions studied
- ANCA Associated Vasculitis — all drugs for ANCA Associated Vasculitis →
- Sjogren's Syndrome — all drugs for Sjogren's Syndrome →
Sponsor
University Hospital, Montpellier
Who can join
18 and older, any sex, with ANCA Associated Vasculitis or Sjogren's Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
ANCA vasculitis and Sjögren syndrome are two rare diseases, and even more rarely associated. These two conditions have specific organ involvements, and specific follow-up. The Investigators hypothesise that patients with co-occurrence of these two diseases may have a singular clinical course.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04895878
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ANCA Associated Vasculitis
Currently open trials in the same condition.
- NCT07203404 — A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. · EARLY_PHASE1 · recruiting
- NCT06548607 — Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT06508346 — Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV · recruiting
- NCT06373081 — Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease · NA · recruiting
- NCT06277427 — Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells · NA · recruiting
Other University Hospital, Montpellier trials
Trials by the same sponsor.
- NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
- NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
- NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
- NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
- NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04895878 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
- Last refreshed: 14 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04895878.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing